{"result": "(\"entity\"<|>BN<|>ORGANIZATION<|>BN is a medication studied for weight loss in patients with obesity and comorbidities, including type 2 diabetes mellitus.)\n##\n(\"entity\"<|>BUPROPION<|>ORGANIZATION<|>Bupropion is a medication used in combination with naltrexone for weight loss treatment.)\n##\n(\"entity\"<|>NALTREXONE<|>ORGANIZATION<|>Naltrexone is a medication that blocks the action of endorphins and is used in combination with bupropion for weight loss.)\n##\n(\"entity\"<|>COR<|>EVENT<|>COR refers to the Contrave Obesity Research studies that evaluated the effectiveness of BN in weight loss.)\n##\n(\"entity\"<|>LIRAGLUTIDE<|>ORGANIZATION<|>Liraglutide is a GLP-1 analog used for weight management and is released in the intestines after food intake.)\n##\n(\"entity\"<|>DIABETES MELLITUS TIPO 2<|>GEO<|>Type 2 diabetes mellitus is a chronic condition that affects the way the body processes blood sugar (glucose).)\n##\n(\"entity\"<|>PACIENTES<|>PERSON<|>Patients involved in the studies for weight loss treatments with BN, bupropion, and naltrexone.)\n##\n(\"relationship\"<|>BUPROPION<|>NALTREXONE<|>Bupropion and naltrexone are used in combination for weight loss treatment in patients with obesity<|>8)\n##\n(\"relationship\"<|>BN<|>COR<|>The COR studies evaluated the effectiveness of BN in weight loss<|>7)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>BN<|>Liraglutide is mentioned as a treatment option alongside BN for weight management<|>5)\n##\n(\"relationship\"<|>DIABETES MELLITUS TIPO 2<|>BN<|>BN is studied in patients with type 2 diabetes mellitus as part of its effectiveness in weight loss<|>6)\n##\n(\"relationship\"<|>PACIENTES<|>BN<|>Patients are the subjects of the studies evaluating the effectiveness of BN<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: a. Las neuronas POMC simultánea-                      confianza). En el caso de BN se constató este supuesto,\nmente liberan una β-endorfina que actúa sobre los re-                  pero se desvelaron los resultados antes de finalizar el\nceptores opiodes-μ. La β-endorfina reduce la liberación                estudio previsto a 5 años. Así que no se obtendrán re-\nde α-MSH desde las neuronas POMC, por un mecanis-                      sultados definitivos con un nuevo estudio de seguridad\nmo de control retroalimentado. La naltrexona bloquea-                  cardiovascular hasta 2022.\nría esta acción de feedback de la endorfina, prolongan-                   Contraindicaciones: BN se absorbe mejor con comi-\ndo así la acción anorexígena de la α-MSH.                              das grasas, por lo que puede interferir con la acción de\n   La administración combinada de bupropiónSR (sustai-                 fármacos anticomiciales y precipitar crisis epilépticas.\nned release) (360 mg) y naltrexonaSR (32 mg) [BN], ha                  BN está contraindicado en embarazadas y lactantes, en\nsido estudiado en tres ensayos clínicos de 56 semanas                  pacientes con HTA descontrolada, en trastornos del\nde duración en más de 3000 pacientes con sobrepeso y                   comportamiento alimentario (anorexia nerviosa y buli-\nobesidad con comorbilidades, incluyendo un grupo con                   mia), en la depresión grave, en pacientes en tratamien-\ndiabetes mellitus tipo 2 (estudios COR: Contrave Obesity               to con IMAO, en los que están en fase de retirada brus-\nReasearch). Los promedios de pérdida de peso oscilaron                 ca de alcohol o en tratamiento con mórficos9.\nentre 5-6,4% para BN            versus   1,2 a 1,8% con place-            Debe prestarse especial atención a la presencia de\nbo17-19. Aproximadamente un 50% de los pacientes per-                  arritmia cardiaca, glaucoma de ángulo estrecho, mi-\ndieron ≥ 5% del peso inicial frente a un 17% del grupo                 grañas persistentes, crisis de ansiedad generalizada,\nplacebo (OR 3,96; IC 95% 3,03-5,11)9. Un cuarto estu-                  trastorno bipolar, alteraciones hepáticas o renales. Bu-\ndio se realizó en un grupo de pacientes con obesidad                   propión inhibe el CYP2D6 y puede aumentar las con-\nque recibió tratamiento intensivo de cambios en el estilo              centraciones       de    antidepresivos      (ISSR    y   tricíclicos),\nde vida (28 sesiones en un año) (estudio COR-BMOD)20,                  antipsicóticos (haloperidol, risperidona y tioridazina),\nsiendo la pérdida de peso mayor que en los estudios                    beta-bloqueantes (metoprolol) y antiarrítmicos tipo 1C\nprevios: 9,3% para BN frente a 5,1% del grupo placebo                  (propafenona, flecainida). Considerar la reducción de\n(diferencia de un 4,2%, incluso algo inferior a los estu-              dosis cuando se utilice BN.\ndios COR). Con esta modalidad de terapia conductual                       Los inductores del CYP2B6 (por ejemplo, ritonavir, lo-\nun 66,4 y 44,5% de los pacientes perdieron más de 5%                   pinavir, efavirenz, carbamazepina, fenobarbital y feni-\ny del 10% del peso basal respectivamente.                              toína) pueden reducir la eficacia del fármaco, así que\n   Los efectos secundarios más destacables son: cefa-                  debe evitarse su uso concomitante. Por último, NB pue-\nlea, insomnio, sequedad de boca, mareos, náuseas,                      de producir interferencias farmacológicas al proporcio-\nvómitos y estreñimiento, que suelen minimizarse trans-                 nar resultados falsos-positivos en orina por anfetaminas.\ncurridos 4-6 semanas de tratamiento. Por este motivo,\nse recomienda que el paciente realice un progresivo                    3.3.    Liraglutida 3 mg\nescalamiento de dosis a lo largo de 4 semanas: comen-\nzando con 1 comp. por la mañana e incrementando                           Liraglutida es un análogo de la incretina GLP-1 (Gluca-\ncada semana en 1 comp. hasta llegar a 4 comp./día,                     gon Like Peptide-1) que se libera en las células L intesti-\ndistribuidos en 2 tomas. La última dosis se recomienda                 nales tras la ingesta de alimentos. Liraglutida tiene una\nque se tome por la\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}